Source: Benzinga
Biotech stocks found themselves among gains in the week ended Sept. 18, with conference presentations, IPO news flow and updates on coronavirus vaccine/antibody candidates catalyzing some strong moves. A big-ticket M&A was announced at the start of the week. Gilead Sciences Inc. (NASDAQ: GILD agreed to buy Immunomedics Inc. (NASDAQ: IMMU ), which has a commercial antibody drug conjugate in the market. Three biopharma companies and a dialysis equipment maker debuted on Wall Street, with the former group raising combined gross proceeds of $522 million. Here’re the catalytic events for the unfolding week: Conferences 56th annual meeting of the European Association for the Study of Diabetes, or EASD: Sept. 21-25 2020 American Academy of Neurology Science Highlights: Sept. 23-24 14th annual Sickle Cell Disease Research and Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting (virtual event): Sept. 23-25 PDUFA Dates The FDA could announce its decision on Bausch Health Companies Inc’s (NYSE: BHC ) NDA for EM-100, …
